\-\ Texto\\:\\ \ \(0\)\
\-\ pain\\ over\\ right\\ hip\\ and\\ with\\ flexion\\ and\\ extension\\ at\\ the\\ waist\\.\ \(0\)\
\-\ treatment\\ is\\ primarily\\ by\\ surgical\\ resection\\ with\\ radiotherapy\\ and\\ chemotherapy\\.\\ \\ \\ this\\ patient\\ is\\ newly\\ diagnosed\\ and\\ the\\ specific\\ treatment\\ and\\ followup\\ plan\\ has\\ not\\ yet\\ been\\ established\\.\ \(0\)\
\-\ on\\ conventional\\ radiographs\\ this\\ lesion\\ is\\ characteristically\\ permeative\\ with\\ poorly\\ defined\\ margins\\,\\ often\\ lytic\\.\\ \\ there\\ may\\ be\\ periosteal\\ new\\ bone\\ formation\\ with\\ an\\ \\‚\\Ä\\úonion\\ skin\\‚\\Ä\\ù\\ appearance\\.\\ \\ ct\\ and\\ mri\\ clearly\\ delineate\\ the\\ often\\ very\\ large\\ soft\\ tissue\\ component\\,\\ especially\\ in\\ the\\ flat\\ bones\\ of\\ the\\ pelvis\\ and\\ thoracic\\ cage\\.\\ \\ bone\\ scintigraphy\\ is\\ useful\\ for\\ the\\ early\\ detection\\ of\\ bone\\ metastases\\.\\ \\ metastatic\\ lesions\\ are\\ seen\\ in\\ the\\ lung\\,\\ skeletal\\ system\\,\\ and\\ lymph\\ nodes\\ and\\ are\\ present\\ in\\ 15\\-25\\%\\ of\\ children\\ at\\ presentation\\.\ \(0\)\
\-\ \\ \\ mri\\ is\\ valuable\\ for\\ assessing\\ medullary\\ extension\\ and\\ the\\ soft\\-tissue\\ component\\ of\\ the\\ tumor\\.\\ \\ the\\ soft\\-tissue\\ component\\ of\\ the\\ tumor\\ decreases\\ after\\ therapy\\,\\ but\\ the\\ medullary\\ abnormality\\ remains\\.\\ \\ dynamic\\ enhanced\\ mri\\ has\\ been\\ used\\ to\\ assess\\ tumor\\ response\\.\ \(0\)\
\-\ ewing\\ sarcoma\ \(0\)\
\-\ ewing\\ sarcoma\ \(0\)\
\-\ non\\-hodgkin\\ lymphoma\ \(0\)\
\-\ osteosarcoma\ \(92\)\
\-\ osteomyelitis\ \(170\)\
\-\ metastatic\\ neuroblastoma\ \(2\)\
\-\ 13\\ yo\\ female\\ with\\ right\\ hip\\ and\\ pelvis\\ pain\\.\ \(1\)\
\-\ this\\ is\\ a\\ good\\ example\\ of\\ the\\ aggressiveness\\ of\\ ewing\\ sarcoma\\ \\ as\\ well\\ as\\ how\\ large\\ an\\ associated\\ soft\\ tissue\\ mass\\ can\\ be\\.\\ \\ the\\ imaging\\ findings\\ alone\\ cannot\\ diagnose\\ ewing\\ sarcoma\\,\\ but\\ they\\ do\\ demonstrate\\ a\\ very\\ aggressive\\ process\\ consistent\\ with\\ a\\ malignant\\ process\\.\\ \\ biopsy\\ showed\\ a\\ ewing\\ sarcoma\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ ewing\\:\\ 0\\.39194768538627045\ \(0\)\
\-\ sarcoma\\:\\ 0\\.30486465011187786\ \(0\)\
\-\ the\\:\\ 0\\.20304456807196775\ \(0\)\
\-\ component\\:\\ 0\\.18686308114004319\ \(0\)\
\-\ and\\:\\ 0\\.16521289126718025\ \(0\)\
\-\ soft\\:\\ 0\\.1547826387988157\ \(0\)\
\-\ tissue\\:\\ 0\\.15251451736727464\ \(0\)\
\-\ medullary\\:\\ 0\\.12856536348578204\ \(0\)\
\-\ is\\:\\ 0\\.1194307988612347\ \(0\)\
\-\ bone\\:\\ 0\\.1189767201380932\ \(0\)\
\-\ aggressiveness\\:\\ 0\\.11623827472324787\ \(0\)\
\-\ tumor\\:\\ 0\\.1140545688227733\ \(0\)\
\-\ mri\\:\\ 0\\.11192925713351064\ \(0\)\
\-\ hip\\:\\ 0\\.11166864546781496\ \(0\)\
\-\ process\\:\\ 0\\.1090282103216606\ \(0\)\
\-\ onion\\:\\ 0\\.10456298566168956\ \(0\)\
\-\ very\\:\\ 0\\.10428182959299932\ \(0\)\
\-\ extension\\:\\ 0\\.10290399084569572\ \(0\)\
\-\ pelvis\\:\\ 0\\.10167190514212537\ \(0\)\
\-\ of\\:\\ 0\\.09956818950580373\ \(0\)\
\-\ often\\:\\ 0\\.09485321092850127\ \(0\)\
\-\ permeative\\:\\ 0\\.09451653722044263\ \(0\)\
\-\ valuable\\:\\ 0\\.09340784655856035\ \(0\)\
\-\ waist\\:\\ 0\\.0923879500160657\ \(0\)\
\-\ cage\\:\\ 0\\.09144367330719745\ \(0\)\
\-\ delineate\\:\\ 0\\.0889697558999988\ \(0\)\
\-\ characteristically\\:\\ 0\\.08689895520993775\ \(0\)\
\-\ assessing\\:\\ 0\\.08627727559426174\ \(0\)\
\-\ decreases\\:\\ 0\\.08627727559426174\ \(0\)\
\-\ with\\:\\ 0\\.08539515555026371\ \(0\)\
\-\ been\\:\\ 0\\.08469357908488999\ \(0\)\
\-\ newly\\:\\ 0\\.08405568137425534\ \(0\)\
\-\ dynamic\\:\\ 0\\.08216452783314127\ \(0\)\
\-\ diagnose\\:\\ 0\\.08131475270380865\ \(0\)\
\-\ metastatic\\:\\ 0\\.07972758047133821\ \(0\)\
\-\ plan\\:\\ 0\\.07906031850539841\ \(0\)\
\-\ radiotherapy\\:\\ 0\\.07872051424609694\ \(0\)\
\-\ established\\:\\ 0\\.07838953707725409\ \(0\)\
\-\ how\\:\\ 0\\.07685250676869082\ \(0\)\
\-\ detection\\:\\ 0\\.07574381610680854\ \(0\)\
\-\ scintigraphy\\:\\ 0\\.07548108711702292\ \(0\)\
\-\ flat\\:\\ 0\\.07522366614837943\ \(0\)\
\-\ this\\:\\ 0\\.07492706801389024\ \(0\)\
\-\ conventional\\:\\ 0\\.07424303590681305\ \(0\)\
\-\ yet\\:\\ 0\\.07355411653316125\ \(0\)\
\-\ large\\:\\ 0\\.07283704484257097\ \(0\)\
\-\ example\\:\\ 0\\.07248273747793275\ \(0\)\
\-\ but\\:\\ 0\\.07188515793234153\ \(0\)\
\-\ alone\\:\\ 0\\.07149449785747948\ \(0\)\
\-\ primarily\\:\\ 0\\.0697219358043922\ \(0\)\
\-\ useful\\:\\ 0\\.06939520240064019\ \(0\)\
\-\ treatment\\:\\ 0\\.06924692995690272\ \(0\)\
\-\ remains\\:\\ 0\\.06923492475818592\ \(0\)\
\-\ osteosarcoma\\:\\ 0\\.06876584462590846\ \(0\)\
\-\ clearly\\:\\ 0\\.06846245161256456\ \(0\)\
\-\ assess\\:\\ 0\\.0671800614117504\ \(0\)\
\-\ response\\:\\ 0\\.06704522518453862\ \(0\)\
\-\ neuroblastoma\\:\\ 0\\.06677975923747313\ \(0\)\
\-\ has\\:\\ 0\\.06640028680684425\ \(0\)\
\-\ skeletal\\:\\ 0\\.06589190433843797\ \(0\)\
\-\ poorly\\:\\ 0\\.06564919405593965\ \(0\)\
\-\ followup\\:\\ 0\\.06417515448394835\ \(0\)\
\-\ periosteal\\:\\ 0\\.06396278449176149\ \(0\)\
\-\ aggressive\\:\\ 0\\.0628540938298792\ \(0\)\
\-\ osteomyelitis\\:\\ 0\\.06266248263160358\ \(0\)\
\-\ margins\\:\\ 0\\.06201366369881471\ \(0\)\
\-\ flexion\\:\\ 0\\.06174540316799695\ \(0\)\
\-\ nodes\\:\\ 0\\.06174540316799695\ \(0\)\
\-\ lytic\\:\\ 0\\.06122525320956782\ \(0\)\
\-\ do\\:\\ 0\\.060244622968001454\ \(0\)\
\-\ children\\:\\ 0\\.05955570359434964\ \(0\)\
\-\ good\\:\\ 0\\.059116284029955314\ \(0\)\
\-\ be\\:\\ 0\\.05897035917410284\ \(0\)\
\-\ metastases\\:\\ 0\\.058761333374139364\ \(0\)\
\-\ bones\\:\\ 0\\.05848432453912114\ \(0\)\
\-\ as\\:\\ 0\\.05839985422658076\ \(0\)\
\-\ formation\\:\\ 0\\.05762350502618344\ \(0\)\
\-\ especially\\:\\ 0\\.05749608491866787\ \(0\)\
\-\ lymph\\:\\ 0\\.056520151287758225\ \(0\)\
\-\ an\\:\\ 0\\.055588586914386715\ \(0\)\
\-\ system\\:\\ 0\\.05545066651701511\ \(0\)\
\-\ enhanced\\:\\ 0\\.055343139258072445\ \(0\)\
\-\ are\\:\\ 0\\.05516089367280952\ \(0\)\
\-\ specific\\:\\ 0\\.05507822525506576\ \(0\)\
\-\ at\\:\\ 0\\.054907681278783795\ \(0\)\
\-\ 13\\:\\ 0\\.054818707026180934\ \(0\)\
\-\ used\\:\\ 0\\.054414168142116526\ \(0\)\
\-\ thoracic\\:\\ 0\\.05431500885127355\ \(0\)\
\-\ in\\:\\ 0\\.05424460408872706\ \(0\)\
\-\ skin\\:\\ 0\\.05407043503611121\ \(0\)\
\-\ abnormality\\:\\ 0\\.05286922185087378\ \(0\)\
\-\ diagnosed\\:\\ 0\\.0526506589523354\ \(0\)\
\-\ early\\:\\ 0\\.05239323798369191\ \(0\)\
\-\ pain\\:\\ 0\\.052018349222455885\ \(0\)\
\-\ they\\:\\ 0\\.051934396425342144\ \(0\)\
\-\ defined\\:\\ 0\\.05185271727021666\ \(0\)\
\-\ malignant\\:\\ 0\\.051812073202046706\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.05161077510446013\ \(0\)\
\-\ biopsy\\:\\ 0\\.05094921469075812\ \(0\)\
\-\ new\\:\\ 0\\.05028426880407941\ \(0\)\
\-\ presentation\\:\\ 0\\.050034768994821927\ \(0\)\
\-\ showed\\:\\ 0\\.048412989557604744\ \(0\)\
\-\ right\\:\\ 0\\.048195811628860795\ \(0\)\
\-\ radiographs\\:\\ 0\\.04714217614154075\ \(0\)\
\-\ resection\\:\\ 0\\.04659168428727991\ \(0\)\
\-\ yo\\:\\ 0\\.045409127305097816\ \(0\)\
\-\ lung\\:\\ 0\\.044214797019851114\ \(0\)\
\-\ for\\:\\ 0\\.04406020388981952\ \(0\)\
\-\ appearance\\:\\ 0\\.0438186437264595\ \(0\)\
\-\ lymphoma\\:\\ 0\\.043288096456504936\ \(0\)\
\-\ therapy\\:\\ 0\\.041761936266182215\ \(0\)\
\-\ lesions\\:\\ 0\\.0417435097921576\ \(0\)\
\-\ over\\:\\ 0\\.04041575520330492\ \(0\)\
\-\ consistent\\:\\ 0\\.03941118266093438\ \(0\)\
\-\ associated\\:\\ 0\\.038310160915664845\ \(0\)\
\-\ imaging\\:\\ 0\\.03819814345076878\ \(0\)\
\-\ can\\:\\ 0\\.03814250185768806\ \(0\)\
\-\ demonstrate\\:\\ 0\\.037786636065263286\ \(0\)\
\-\ present\\:\\ 0\\.03729675706353611\ \(0\)\
\-\ may\\:\\ 0\\.0365771120792219\ \(0\)\
\-\ findings\\:\\ 0\\.03587269631622628\ \(0\)\
\-\ surgical\\:\\ 0\\.035327018446473256\ \(0\)\
\-\ after\\:\\ 0\\.03526042297484011\ \(0\)\
\-\ well\\:\\ 0\\.03519417375505685\ \(0\)\
\-\ female\\:\\ 0\\.035073604296091215\ \(0\)\
\-\ lesion\\:\\ 0\\.03484654695493237\ \(0\)\
\-\ seen\\:\\ 0\\.034219255176750306\ \(0\)\
\-\ by\\:\\ 0\\.030866037153763033\ \(0\)\
\-\ there\\:\\ 0\\.028920920992799484\ \(0\)\
\-\ not\\:\\ 0\\.028694095759417414\ \(0\)\
\-\ mass\\:\\ 0\\.027763523327370605\ \(0\)\
\-\ ct\\:\\ 0\\.027671656277890335\ \(0\)\
\-\ patient\\:\\ 0\\.023640605940675186\ \(0\)\
\-\ on\\:\\ 0\\.02195195447782624\ \(0\)\
\-\ to\\:\\ 0\\.018170972183697134\ \(0\)\
